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onset of sustained ischemia, and was maintained for the duration of 20 min of coronary
occlusion. The IN group received 15 min of waiting period followed by 20 min of ischemia.
The ischemic and the non-ischemic tissues in the IN and IH hearts were separated and
processed for tissue adenosine triphosphate (ATP), creatine phosphate (CP), lactate and
glycogen determination.
Results: Ischemia decreased ATP, CP and glycogen content (by 67%, 73% and 73%
respectively) and caused 13-fold accumulation of lactate in the ischemic vs. the non-
ischemic area in the IN hearts. However, mild, regional hypothermia preserved ATP and
glycogen stores in the ischemic area of IH rabbits by 43% and 83% respectively (i.e.
1.20±0.11 µmol/g in the IH vs. 0.84±0.06 µmol/g in the IN group, p<0.05 for ATP; and
1.32±0.15 mg/g in the IH vs. 0.72±0.07 mg/g in the IN group, p<0.05 for glycogen). In
addition, mild regional hypothermia caused a trend towards the preservation of CP by
14% in the ischemic tissue (0.81±0.15 µmol/g in the IH group vs. 0.71±0.07 µmol/g in the
IN group).
Conclusion: It is likely that the mechanism whereby mild regional hypothermia reduces
infarct size is by slowing the metabolism of the crucial high energy phosphate, ATP. This
is the first study to show that in a model of regional ischemia local therapy with very mild
reductions in myocardial temperature preserves ATP within the ischemic risk zone.
1041-100 Hydrochlorothiazide Further Improves Survival During 
Angiotensin-Converting Enzyme Inhibitor Therapy After 
Experimental Myocardial Infarction
Bart Westendorp, Regien G. Schoemaker, Hendrik Buikema, Wiek H. van Gilst, Dirk J. 
van Veldhuisen, University of Groningen, Groningen, The Netherlands, University 
hospital of Groningen, Groningen, The Netherlands
Background: Efficacy of ACE inhibitor (ACEi) treatment after myocardial infarction may
be positively influenced by concomitant sodium depletion with diuretics, as is reported in
treatment of renal proteinuric disease and hypertension.
Hypothesis: Treatment with the diuretic hydrochlorothiazide (HCT) augments beneficial
effects of chronic ACEi treatment after MI.
Methods: Rats were subjected to coronary ligation to induce MI. After 2 weeks, rats were
randomized to 15 mg/kg/day quinapril only (QUI, n=44), or 50 mg/kg/day HCT in addition
to quinapril (QUI-HCT, n=46). Survival was checked for 62 weeks. LV function and neuro-
hormones were measured in survivors after 62 weeks and in a separate batch of rats
treated for 35 weeks according to the same procedures (QUI, n=6; QUI-HCT, n=5).
Results: Results are shown in the table. Until week 35 survival was significantly
improved by additional HCT (p<0.05). Urinary protein excretion and left ventricular end-
diastolic pressures (LVEDP) were decreased in QUI-HCT rats at week 35. Plasma renin
activity (PRA) was lower in QUI-HCT rats at 35 weeks. After 62 weeks, differences had
waned off.
Conclusion: Adding of HCT to QUI treatment further improved survival, neurohumoral
status, and proteinuria during the early chronic phase of experimental post-MI LV dys-
function. The results suggest that combined therapy with diuretics and ACEi can be a
safe treatment to improve prognosis of post-MI LV dysfunction.
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1042-77 Haptoglobin Polymorphism Is Associated With Short-
Term Mortality and Heart Failure in Patients With 
Diabetes and Acute Myocardial Infarction
Mahmoud Suleiman, Doron Aronson, Michael Kapeliovich, Walter Markiewicz, Haim 
Hammerman, Shimon A. Reisner, Rachel Lotan, Michael Shochat, Nina S. Levy, Andrew 
P. Levy, Rambam, Haifa, Israel
Introduction: Patients (pts) with diabetes presenting with acute myocardial infarction
(AMI) have a poor in-hospital outcome primarily due to an increased incidence of death
and heart failure. The susceptibility to diabetic complications is partially determined by
genetic factors. Haptoglobin (Hp) phenotype is related to the risk of developing both
microvascular and macrovascular complications of diabetes. We prospectively tested the
hypothesis that Hp phenotype is related to the outcome of pts with diabetes presenting
with AMI.
Methods: We enrolled 798 consecutive pts with AMI. The primary endpoint was 30-days
mortality or heart failure. Infarct size was determined by echocardiography on day 2-3.
Multivariate logistic regression was used to calculate adjusted ORs and to test for inter-
action between Hp phenotype and diabetes with respect to the primary endpoint.
Results: At 30-days, 237 patients (29.7%) died or developed heart failure. Multivariate
logistic regression identified a strong protective effect of Hp 1-1 phenotype with regard to
the primary endpoint of 30-days mortality or heart failure (OR for Hp 1-1 versus Hp 2-1 or
Hp 2-2: 0.43; 95% CI 0.22-0.84, P = 0.01). The interaction between Hp phenotype and
diabetes was highly significant in unadjusted (P = 0.008) and adjusted (P = 0.005) logis-
tic regression models. In a stratified analyses, Hp 1-1 phenotype was not related to out-
come among pts without diabetes (Adjusted OR 0.78; 95% CI 0.33-1.82, P = 0.56). By
contrast, Hp 1-1 phenotype was associated with a strong protective effect with regard to
the primary endpoint among pts with diabetes (Adjusted OR 0.21; 95% CI 0.07-0.62, P =
0.005). Among pts with diabetes, Hp 1-1 was also associated with a smaller infarct size
compared with Hp 2-1/2-2 (echocardiographic wall motion score index 1.70 ± 0.03 vs
1.45 ± 0.07, P = 0.005), whereas in pts without diabetes there was no significant differ-
ence. Conclusion: Hp phenotype may be an important genetic marker that affects the
outcome of patients with diabetes and AMI. Better understanding of the mechanism
underlying Hp effect may help to reduce morbidity and mortality in patients with diabetes
in the setting of AMI.
1042-78 Does Chronic Infection With Chlamydia Pneumoniae 
Influence the Prognosis of Acute Coronary Syndromes? 
Insights From a Nested Matched Case-Control 
Substudy of the GUSTO IV Acute Coronary Syndromes 
Trial
Cynthia M. Westerhout, Judy Gnarpe, Wei-Ching Chang, Elliot S. Barnathan, Eric 
Boersma, Stefan James, Robert M. Califf, Maarten L. Simoons, Paul W. Armstrong, 
University of Alberta, Edmonton, Canada
Background: Prior studies of chronic Chlamydia pneumoniae(Cpn) infection and
adverse outcomes of ACS are inconclusive, small in sample size and used non-standard-
ized antibody detection methods. Thus, in well-defined non-ST-elevation(NSTE) ACS pts
followed for 1yr, serologically defined chronic Cpn infection may be a significant predictor
of adverse outcomes. Methods: This case-control substudy of GUSTO-IV ACS (n=7800)
randomly selected 295 pts who had 30-day(30d) death or myocardial infarction
(MI)(cases) (with 90% power). Cases were matched to 295 controls on age, sex, CK-MB
and smoking status(potential confounder of Cpn infection). Cpn IgG and IgA titers were
measured in baseline serum with microimmunofluorescence technique. Conditional
logistic regression identified predictors of 30d death/MI and 1yr death. Results: Controls
were similar to cases in Cpn IgG >=1:32 (85% v 80% p>0.1) and IgA >=1:16 (43% v 49%
p=0.07). After baseline adjustment, troponin T was a significant predictor of 30d death/
MI, but CRP, IgG and IgA were not. Given the value of long-term prognosis, a subset was
drawn from 590-pt cohort:138 pts who died at 1y plus its partner in the existing matched
pair who survived 1y(n=276). Pts with IgG>=1:256 were at twice the risk of 1y death and
was independent of CRP, also a significant predictor of 1y death(Figure). Conclusions:
Whereas chronic Cpn infection was not associated with 30d death/MI, it emerged as a
significant independent predictor of long-term death even in the presence of CRP. 
1042-79 Impact of Altered Expression Balance of Matrix 
Metalloproteinases and Tissue Inhibitor of 
Metalloproteinases Genes on Coronary Plaque Rupture: 
Results From Quantitative Tissue Analysis Using Real-
Time Reverse Transcriptase-Polymerase Chain 
Reaction Method
Shuichiro Higo, Shinsuke Nanto, Takeo Higashikata, Hatsue Ishibashi-Ueda, Aiji 
Sakamoto, Hitonobu Tomoike, Masakazu Yamagishi, Kansai Rosai Hospital, Amagasaki, 
Japan, National Cardiovascular Center, Suita, Japan
Background:Previous immunohistochemical studies demonstrated overexpression of
matrix metalloproteinases (MMPs) at the ruptured coronary sites in acute coronary syn-
drome. However, few data exist regarding quantitative analysis of gene expression of
MMPs and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs), in human cor-
onary plaque. Therefore, gene expression of MMPs and TIMPs was quantitatively deter-
mined by real-time RT-PCR.
Method and Results:Tissue samples of the coronary plaque were obtained from 28 cor-
onary patients underwent directional atherectomy. Amounts of the cDNAs for MMP-1, 2,
3 and 9, and TIMP-1, 2, 3 in each cDNA mixture were determined by real-time RT-PCR
method, and normalized with glutaraldehyde 3-dehydrogenase as a reference gene. In
tissue samples from 8 patients with unstable disease. the gene for MMP-9 (5.00 + 1.57)
was significantly augmented to express than those from 20 patients with stable patients
(1.97 + 1.14, p<0.05). There were no statistical significance in MMP-1 (0.41 + 0.19 Ver-
sus 0.34 + 0.10), MMP-2 (2.04 + 0.34 Versus1.85 + 0.22) and MMP-3 (1.36 + 1.06 Ver-
sus 0.28 + 0.08) gene expression. Although the expression levels of TIMP-1, TIMP-2 and
TIMP-3 genes tended higher in unstable (30.19 +5 .11, 4.45 + 0.89 and 6.85 + 2.14) than
that in stable patients (26.33 + 6.24, 3.75 + 1.06 and 4.68 + 1.69), the ratios of MMP-9/
Table
Mortality 
(%)
Urinary protein 
(mg/24h)
LVEDP (mm 
Hg)
PRA (ng Ang1/
mL/h)
QUI week 35 11 9.5±0.9 10±2 192±27
QUI-HCT week 35 0* 7.4±0.5* 7±2 100±19*
QUI week 62 23 9.5±0.6 12±3 73±9
QUI-HCT week 62 22 8.0±0.6 12±3 65±6
